全文获取类型
收费全文 | 26793篇 |
免费 | 2934篇 |
国内免费 | 861篇 |
专业分类
耳鼻咽喉 | 201篇 |
儿科学 | 460篇 |
妇产科学 | 477篇 |
基础医学 | 3374篇 |
口腔科学 | 505篇 |
临床医学 | 4991篇 |
内科学 | 5067篇 |
皮肤病学 | 189篇 |
神经病学 | 2043篇 |
特种医学 | 2056篇 |
外国民族医学 | 2篇 |
外科学 | 1682篇 |
综合类 | 3022篇 |
现状与发展 | 2篇 |
预防医学 | 2145篇 |
眼科学 | 309篇 |
药学 | 1814篇 |
20篇 | |
中国医学 | 1168篇 |
肿瘤学 | 1061篇 |
出版年
2024年 | 64篇 |
2023年 | 484篇 |
2022年 | 657篇 |
2021年 | 1439篇 |
2020年 | 1239篇 |
2019年 | 1247篇 |
2018年 | 1199篇 |
2017年 | 1216篇 |
2016年 | 1169篇 |
2015年 | 1126篇 |
2014年 | 1734篇 |
2013年 | 2148篇 |
2012年 | 1497篇 |
2011年 | 1514篇 |
2010年 | 1252篇 |
2009年 | 1101篇 |
2008年 | 1162篇 |
2007年 | 1081篇 |
2006年 | 1007篇 |
2005年 | 832篇 |
2004年 | 762篇 |
2003年 | 751篇 |
2002年 | 613篇 |
2001年 | 579篇 |
2000年 | 506篇 |
1999年 | 392篇 |
1998年 | 372篇 |
1997年 | 321篇 |
1996年 | 338篇 |
1995年 | 268篇 |
1994年 | 223篇 |
1993年 | 258篇 |
1992年 | 244篇 |
1991年 | 186篇 |
1990年 | 176篇 |
1989年 | 152篇 |
1988年 | 168篇 |
1987年 | 169篇 |
1986年 | 134篇 |
1985年 | 122篇 |
1984年 | 103篇 |
1983年 | 71篇 |
1982年 | 97篇 |
1981年 | 77篇 |
1980年 | 84篇 |
1979年 | 58篇 |
1978年 | 40篇 |
1977年 | 37篇 |
1976年 | 40篇 |
1975年 | 21篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
目的 探索模拟马术训练对后循环卒中共济失调患者姿势控制、平衡、步行和日常生活活动能力的效果。 相似文献
3.
4.
《Pediatric clinics of North America》2015,62(6):1463-1477
5.
Ki-Yong An Andria R. Morielli Dong-Woo Kang Christine M. Friedenreich Donald C. McKenzie Karen Gelmon John R. Mackey Robert D. Reid Kerry S. Courneya 《International journal of cancer. Journal international du cancer》2020,146(1):150-160
The Combined Aerobic and Resistance Exercise (CARE) Trial compared different types and doses of exercise performed during breast cancer chemotherapy. Here, we report the longer-term follow-up of patient-reported outcomes, health-related fitness and exercise behavior at 6, 12 and 24 months postintervention. A multicenter trial in Canada randomized 301 breast cancer patients initiating chemotherapy to thrice weekly, supervised exercise consisting of a standard dose of 25–30 min of aerobic exercise (STAN; n = 96), a higher dose of 50–60 min of aerobic exercise (HIGH; n = 101) or a combined dose of 50–60 min of aerobic and resistance exercise (COMB; n = 104) performed for the duration of chemotherapy (median of 17 weeks). Primary outcomes were patient-reported outcomes including quality of life, cancer-related symptoms and psychosocial outcomes. Secondary outcomes were objective health-related fitness (assessed at 12 months only) and self-reported exercise behavior. A total of 269 (89.4%) participants completed patient-reported outcomes at all three follow-up time points and 263 (87.4%) completed the health-related fitness assessment at 12-month follow-up. COMB was significantly superior to (i) STAN for sleep quality at 6-month follow-up (p = 0.027); (ii) HIGH for upper body muscular endurance at 12-month follow-up (p = 0.020); and (iii) HIGH for meeting the resistance exercise guideline at 6-month follow-up (p = 0.006). Moreover, self-reported meeting of the combined exercise guideline during follow-up was significantly associated with better patient-reported outcomes and health-related fitness. Performing combined exercise during and after breast cancer chemotherapy may result in better longer-term patient-reported outcomes and health-related fitness compared to performing aerobic exercise alone. 相似文献
6.
7.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
8.
Hélène Person Francis Guillemin Thierry Conroy Michel Velten Christine Rotonda 《International journal of cancer. Journal international du cancer》2020,146(7):1827-1835
Women with breast cancer are increasingly being cured of the disease but fatigue remains the most frequently reported symptom. The aims of our study were to identify distinct trajectories in four fatigue dimensions during 2 years after breast cancer surgery and to explore the demographic, clinical and personality characteristics associated with these profiles. We included women from the prospective longitudinal multicenter FATSEIN cohort in France. They completed the Multidimensional Fatigue Inventory for nine follow-ups over 24 months after surgery. A group-based trajectory model identified distinct trajectories in each fatigue dimension. Multinomial logistic regression determined the factors associated with each profile. From the 459 women followed, 3–5 fatigue trajectories were revealed in each fatigue dimension, from its absence to its severest degree. In our multivariate analysis, the risk of severe fatigue was decreased in all dimensions by a high quality of life before surgery (measured by the European Organization for Research and Treatment of Cancer 30-item QoL questionnaire; e.g., for general and physical fatigue: OR = 0.93, 95% CI 0.91, 0.96), especially a high physical and emotional functions for general and physical fatigue, and a high cognitive function for mental fatigue. Both severe mental fatigue and severely reduced motivation worsened with low optimism before surgery (e.g., for mental fatigue: OR = 0.93, 95% CI 0.89, 0.97). Severely reduced activities increased by having chemotherapy (OR = 9.41, 95% CI 2.28, 38.79). Targeting women at risk for severe fatigue can provide early preventive and curative treatment and appropriate psychological support. 相似文献
9.